Viking Therapeutics, Inc. Stock News

Viking Aktie: Explosiver Höhenflug!

Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.

Viking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug. The phase 1 trial results are expected next year, with the Phase 3 (subcutaneous) trial results scheduled for 2027.

VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinic...

Takeover speculation is rife in the industry, particularly with companies with promising obesity drug pipelines. Management reassured investors that there could be substantial value in its lead drug candidate, VK2735.

Stanley Druckenmiller has a fantastic investing track record, delivering a double-digit average annual return over time. The billionaire sold artificial intelligence (AI) leaders Nvidia and Palantir -- stocks that have advanced more than 1,000% over the past few years.

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences.  Details of the company's participation are as follows: Stifel 2025 Healthcare Conferen...

GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809's NASH success. Viking is advancing dual therapies amid a $150 billion obesity opportunity.